CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma – a meta-analysis of randomized controlled trials

References

• Swerdlow S, Campo E, Harris N, editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. IARC Press: Lyon; 2008.
   Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New Engl J Med 1993;329:987–94.
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373–80.
   PubMed Web of Science ®Google Scholar
• Norton L. Conceptual and practical implications of breast tissue geometry: Toward a more effective, less toxic therapy. Oncologist 2005;10:370–81.
   PubMed Web of Science ®Google Scholar
• Bonilla L, Ben-Aharon I, Vidal L, Gafter-Gvili A, Leibovici L, Stemmer SM. Dose-dense chemotherapy in nonmetastatic breast cancer: A systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 2010; 102:1845–54.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New Engl J Med 2002;346:235–42.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013–22.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–16.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–91.
   PubMed Web of Science ®Google Scholar
• Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002;31:150–3.
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815–34.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–48.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003;327:557–60.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997;315:629–34.
   PubMed Web of Science ®Google Scholar
• Balzarotti M, Spina M, Sarina B, Magagnoli M, Castagna L, Milan I, et al. Intensified CHOP regimen in aggressive lymphomas: Maximal dose intensity and dose density of doxorubicin and cyclophosphamide. Ann Oncol 2002;13:1341–6.
   PubMed Web of Science ®Google Scholar
• Fridrik MA, Greil R, Hausmaninger H, Krieger O, Oppitz P, Stoger M, et al. Erratum to: Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group For Medical Tumor Therapy. Ann Hematol 2014;93:539–40.
   Google Scholar
• Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, et al. Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. Ann Hematol 2010;89:273–82.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Barca E, Canales M, Cortes M, Vidal MJ, Salar A, Oriol A, et al. Predictive value of interim (1)(8)F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment. Nucl Med Commun 2013;34:946–52.
   PubMed Web of Science ®Google Scholar
• Holte H, Leppa S, Bjorkholm M, Fluge O, Jyrkkio S, Delabie J, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: Results of a phase II Nordic Lymphoma Group study. Ann Oncol 2013;24:1385–92.
   PubMed Web of Science ®Google Scholar
• Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, et al. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol 2002;13:1347–55.
   PubMed Web of Science ®Google Scholar
• Recher C, Coiffier B, Haioun C, Molina TJ, Ferme C, Casasnovas O, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial. Lancet 2011; 378:1858–67.
   PubMed Web of Science ®Google Scholar
• Trumper L, Zwick C, Ziepert M, Hohloch K, Schmits R, Mohren M, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. Ann Oncol 2008;19:538–44.
   Google Scholar
• Vitolo U, Liberati AM, Cabras MG, Federico M, Angelucci E, Baldini L, et al. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: An “Intergruppo Italiano Linfomi” randomized trial. Haematologica 2005;90:793–801.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, et al. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol 2011;29: 3990–8.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381:1817–26.
   PubMed Web of Science ®Google Scholar
• Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03–6B study): A randomised phase 3 trial. Lancet Oncol 2013;14:525–33.
   PubMed Web of Science ®Google Scholar
• Economopoulos T, Psyrri A, Dimopoulos MA, Kalogera-Fountzila A, Pavlidis N, Tsatalas C, et al. CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the Hellenic Cooperative Oncology Group. Cancer J 2007;13:327–34.
   PubMed Web of Science ®Google Scholar
• Ohmachi K, Tobinai K, Kobayashi Y, Itoh K, Nakata M, Shibata T, et al. Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: Final results of the Japan Clinical Oncology Group Study, JCOG 9809. Ann Oncol 2011;22:1382–91.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–41.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626–33.
   PubMed Web of Science ®Google Scholar
• Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: Results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2003;14:881–93.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang J, Wang J. Biweekly CHOP therapy improves therapeutic effect in the non-GCB subtype of diffuse large B-cell lymphoma. Cent Eur J Med 2007;2:488–98.
   Web of Science ®Google Scholar
• Zhang Q, Wang J, Yu Z, Zhuang Y, Ma W, Jin S, et al. The effect of biweekly CHOP and standard CHOP in different subgroups of diffuse large B-cell lymphoma. Onkologie 2009;32:719–23.
   PubMedGoogle Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–16.
   PubMed Web of Science ®Google Scholar